ArticleDiscover oncology2026
Tumor-intrinsic KLRC1 exerts tumor-suppressive functions in colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Colon adenocarcinoma (COAD) represents a prevalent malignant neoplasm within the gastrointestinal tract characterized by significant morbidity and mortality rates, and the majority of patients are in intermediate to advanced stages at the time of diagnosis. Killer cell lectin-like receptor C1 gene (KLRC1) is an inhibitory receptor in the NKG2 receptor family that can be recognized by HLA-E, thereby inhibiting cytotoxic activity and cytokine secretion from NK cells. However, little is known about its function in various cancers, including COAD. In the present study, we revealed that reduced expression of KLRC1 in COAD correlates with adverse prognosis, suboptimal histological characteristics, and more advanced pathological staging. In addition, KLRC1 expression independently predicted progression in COAD patients. According to the functional enrichment analysis, KLRC1 has been implicated in signaling pathways related to the immune response and cellular proliferation. In addition, we verified that KLRC1 was down-regulated in COAD cell lines and that the overexpression of KLRC1 significantly reduced the migration, invasion, and proliferation capacities and xenograft tumor growth of COAD cell lines. Our study elucidates that KLRC1 is a novel prognostic marker and a therapeutic target for COAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.